Acute Lung Injury – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Acute Lung Injury – Drugs In Development, 2024 report and make more profitable business decisions.
Acute lung injury (ALI) is a severe and potentially life-threatening condition characterized by sudden and significant damage to the lungs, resulting in impaired gas exchange and respiratory function. ALI is now often grouped under the broader term acute respiratory distress syndrome (ARDS). ALI can result from various direct causes, including pneumonia, aspiration of gastric contents, near-drowning, inhalation of toxins or smoke, or severe lung infections; or indirect causes, including sepsis (severe infection), severe trauma, multiple blood transfusions, pancreatitis, or other systemic conditions that lead to widespread inflammation.
ALI involves injury to the alveoli (air sacs) and the surrounding lung tissues, causing increased permeability of the alveolar-capillary membrane. This leads to fluid accumulation in the lungs (pulmonary edema), impairing oxygen exchange between the air sacs and blood vessels. Common signs and symptoms of acute lung injury may include severe difficulty breathing or shortness of breath (dyspnea); rapid breathing (tachypnea) and rapid heart rate (tachycardia); severe fatigue, weakness, or confusion due to decreased oxygen levels in the blood; and cyanosis (bluish discoloration of the skin) due to lack of oxygen.
The Acute Lung Injury drugs in development market research report provide comprehensive information on the therapeutics under development for Acute Lung Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Acute Lung Injury | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 56 molecules, with 46 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Acute Lung Injury therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Acute Lung Injury pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Acute Lung Injury treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
A6 Pharmaceuticals LLCAccendatech Co Ltd
Advac Therapeutic LLC
Aqualung Therapeutics Corp
Asklepion Pharmaceuticals LLC
aTyr Pharma Inc
Axolo Pharma Inc
Beijing Northland Biotech Co Ltd
BioAegis Therapeutics Inc
BioSuperior Technology Inc
Bo Jiyuan (Chongqing) Pharmaceutical Technology Co Ltd
Centers of Biomedical Research Network
Ceria Therapeutics Inc
Chengdu Shibeikang Biomedical Technology Co Ltd
Curacle Co Ltd
Enzyvant Sciences Ltd
GEn1E Lifesciences Inc
Haisco Pharmaceutical Group Co Ltd
Hillhurst Biopharmaceuticals Inc
Ildong Pharmaceutical Co Ltd
InflaRx NV
Jiangyin Usun Pharmaceutical Co Ltd
KeViRX Inc
Koutif Therapeutics LLC
MediciNova Inc
Nano Biotherapeutics Inc
Nitrase Therapeutics Inc
OGB1 Inc
Ohio State University
Orbsen Therapeutics Ltd
QX Therapeutics Inc
Radikal Therapeutics Inc
Relief Therapeutics Holding AG
Rubicon Biotechnology Inc
Serpin Pharma LLC
Sigmovir Biosystems Inc
SolAeroMed Inc
The Lundquist Institute
TheraSource LLC
Trove Therapeutics Inc
TurnSole Biologics Kft
University of Louisville
University of Pittsburgh
University of Seville
University of Washington
Vascular BioSciences
Vasomune Therapeutics Inc
Verra Therapeutics LLC
Wenzhou Medical University
Windtree Therapeutics Inc
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Acute Lung Injury reports